Vigilant Capital Management LLC raised its position in shares of AbbVie Inc (NYSE:ABBV) by 7.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 224,739 shares of the company’s stock after purchasing an additional 16,123 shares during the quarter. AbbVie accounts for 2.2% of Vigilant Capital Management LLC’s portfolio, making the stock its 15th largest position. Vigilant Capital Management LLC’s holdings in AbbVie were worth $17,017,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of ABBV. Weaver Consulting Group acquired a new position in AbbVie in the 1st quarter worth about $25,000. Arbor Wealth Management LLC acquired a new position in shares of AbbVie during the second quarter valued at approximately $28,000. Lowe Wealth Advisors LLC raised its holdings in shares of AbbVie by 206.7% during the second quarter. Lowe Wealth Advisors LLC now owns 460 shares of the company’s stock valued at $33,000 after acquiring an additional 310 shares during the last quarter. Horrell Capital Management Inc. acquired a new position in shares of AbbVie during the second quarter valued at approximately $33,000. Finally, TD Capital Management LLC acquired a new position in shares of AbbVie during the second quarter valued at approximately $33,000. Institutional investors and hedge funds own 68.24% of the company’s stock.
In related news, SVP Nicholas Donoghoe acquired 7,525 shares of AbbVie stock in a transaction dated Thursday, August 29th. The shares were acquired at an average cost of $66.19 per share, for a total transaction of $498,079.75. Following the completion of the purchase, the senior vice president now owns 13,090 shares in the company, valued at $866,427.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Henry O. Gosebruch purchased 30,000 shares of the business’s stock in a transaction on Monday, July 29th. The stock was acquired at an average price of $67.28 per share, for a total transaction of $2,018,400.00. Following the completion of the purchase, the executive vice president now owns 75,763 shares of the company’s stock, valued at $5,097,334.64. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 183,077 shares of company stock worth $10,705,751. Insiders own 0.08% of the company’s stock.
Shares of ABBV stock traded up $1.10 during trading hours on Thursday, reaching $75.85. The company had a trading volume of 2,806,226 shares, compared to its average volume of 7,649,877. The stock has a fifty day moving average of $71.18 and a 200-day moving average of $73.73. The company has a market capitalization of $109.05 billion, a price-to-earnings ratio of 9.59, a PEG ratio of 1.50 and a beta of 0.99. AbbVie Inc has a 12-month low of $62.66 and a 12-month high of $94.98.
AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 26th. The company reported $2.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.05. AbbVie had a negative return on equity of 182.70% and a net margin of 12.62%. The business had revenue of $8.26 billion during the quarter, compared to analyst estimates of $8.09 billion. During the same period in the prior year, the business earned $2.00 earnings per share. The business’s revenue was down .3% compared to the same quarter last year. As a group, analysts anticipate that AbbVie Inc will post 8.93 earnings per share for the current fiscal year.
The business also recently disclosed a — dividend, which will be paid on Friday, November 15th. Stockholders of record on Tuesday, October 15th will be paid a $1.07 dividend. This represents a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, October 11th. AbbVie’s payout ratio is currently 54.11%.
ABBV has been the subject of a number of research analyst reports. ValuEngine raised AbbVie from a “strong sell” rating to a “sell” rating in a report on Monday, September 30th. Piper Jaffray Companies increased their target price on AbbVie from $80.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. TheStreet cut AbbVie from a “b-” rating to a “c” rating in a report on Monday, August 26th. Cowen set a $90.00 target price on AbbVie and gave the company a “buy” rating in a report on Tuesday, September 24th. Finally, Svb Leerink raised AbbVie from a “market perform” rating to an “outperform” rating and set a $88.00 target price for the company in a report on Wednesday, June 26th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company. AbbVie presently has an average rating of “Hold” and a consensus price target of $89.97.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Recommended Story: Discount Rate
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.